Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Abbott’s Depakote Off-Label Settlement With DoJ Includes Court Probation

This article was originally published in The Pink Sheet Daily

Executive Summary

In a new twist, Abbott’s CEO and board must certify company’s compliance program with the court’s probation office. The requirements of the $1.5 billion settlement will transfer to Abbvie, the pharma company spinning out of Abbott.

You may also be interested in...

Abbott's TriCor Off-Label, Kickback Settlement Is Fraction of 2012 Agreement

$25m settlement resolves allegations covering 2006-2008 period; Abbott inked $1.5bn settlement with government six years ago involving Depakote promotion. This is DOJ's fourth pharma deal of the year.

Appeals Court Revives RICO Off-Label Suit Against Abbott

Seventh Circuit reinstates employer benefit funds’ complaint over off-label promotion of Depakote, allowing them to make case they were not properly compensated; courts have issued disparate opinions in such cases.

FDA’s New Criminal Investigations Chief Wants Global Reach

Office of Criminal Investigations Director George Karavetsos talks about the Park Doctrine and off-label enforcement in an interview.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts